Antimicrobial treatment is common at end of life. A treatment escalation/limitation plan (TELP) offers the opportunity to avoid non-beneficial treatment in critically ill patients. Our aim was to evaluate antimicrobial prescribing in terminally ill patients, and assess whether it was modified using a TELP.
Methods
Appropriateness of antimicrobial treatment was audited using a priori criteria in 94 consecutive hospital deaths. Prescribing in patients whose death was expected/unexpected, and who had a TELP with/without a ‘ceiling’ for antimicrobials, were compared.
Results
Twenty three of 94 patients (24.5%) were receiving antimicrobials at time of death. This was not influenced by evidence of infection or whether death was expected. The use of a TELP (n = 81) with an antimicrobial ‘ceiling’ (28 with, 53 without) was associated with a significant reduction in antimicrobials administered (28.6% vs 81.1%; p < 0.0005).
Conclusions
Many complex factors contribute to antimicrobial misuse at end of life. An appropriately constructed TELP reduces inappropriate prescribing.
ClarkD, ArmstrongM, AllanA. Imminence of death among hospital inpatients: prevalence cohort study. Palliat Med2014; 28: 474–9.
2.
Cardona-MorrellM, KimJ, TurnerRM. Non-beneficial treatments in hospital at the end of life: a systematic review on extent of the problem. Int J Qual Health Care2016; 28: 456–69.
3.
CarterHE, WinchS, BarnettAG. Incidence, duration and cost of futile treatment in end-of-life hospital admissions. BMJ Open2017; 27: 261–5.
4.
Guardian Newspaper. 13 October 2017.
5.
DaviesSC. Annual Report of the Chief Medical Officer. Volume 2London: Department of Health London; 2011.
6.
FurunoJP, NobleBN, FrommeEK. Should we refrain from antibiotic use in hospice patients?Expert Rev Anti Infect Ther2016; 14: 277–80.
7.
RosenbergJH, AlbrechtJS, FrommeEK. Antimicrobial use for symptom management in patients receiving hospice and palliative care: a systematic review. J Pall Med2013; 16: 1568–74.
8.
ChunED, RodgersPE, VitaleCA. Antimicrobial use in patients receiving palliative care. Am J Hospice Pall Med2010; 27: 261–5.
Helde-FranklingM, BerqvistJ, BergmanP. Antibiotic treatment in end-of-life cancer patients. Cancer2016; 8: 84–94.
11.
WhitePH, KuhlenschmidtHL, VancuraBG. Antimicrobial use in patients with advanced cancer receiving hospice care. J Pain Symptom Manage2003; 25: 438–43.
12.
StielS, KrummN, PestingerM. Antibiotics in palliative medicine - results from a prospective epidemiological investigation from the HOPE survey. Support Care Cancer2012; 20: 325–33.
13.
LightbodyCJ, CampbellJN, HerbisonGP. The impact of a treatment escalation/limitation plan on non-beneficial interventions and harms in patients during their last admission before in-hospital death, using the Structured Judgment Review Method. BMJ Open2018; 8: e024264.
Al-ShaqiMA, AlamiAH, Al-ZahraniAS. The pattern of anti-microbial use for palliative care in-patients during the last week of life. Am J Hospice Pall Med2012; 29: 60–3.
17.
MacedoF, NunesC, LadeiraK. Antimicrobial therapy in palliative care: an overview. Support Care Cancer2018; 26: 1361–7.
18.
MitchellSL, ShafferML, LoebMR. Infection management and multi-drug resistant organisms in nursing home residents with advanced dementia. JAMA Intern Med2014; 174: 1660–7.
19.
DeliaRV, HarrisonK, OystonPC. Targeting the cytokine storm for therapeutic benefit. Clin Vaccine Immunol2013; 20: 319–27.
20.
ServidSA, NobleBN, FrommeEK. Clinical intentions of antibiotics prescribed upon discharge to hospice care. J Am Geriatr Soc2018; 66: 565–9.
21.
TaylorDR, LightbodyCJ. Futility and appropriateness: challenging words, important concepts. Postgrad Med J2018; 94: 238–43.
DattaR, Juthani-MehtaM. Burden and management of multidrug resistant organisms in palliative care. Pall Care2017; 10:1178224217749233.
24.
DancerSJ, KirkatrickP, CorcoranDS. Approaching zero: temporal effects of a restrictive antibiotic policy on hospital acquired C. difficile. Int J Antimicrob Agents2013; 41: 137–42.
25.
SeppalaH. Klaukka T, Vuopio-Varkila J et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med1997; 337: 441–6.
